Expression Analysis Hires Director of Business Development

DURHAM, N.C.--(BUSINESS WIRE)-- EA, long known as an industry leader in genetic analysis, announced an addition to their management team, Jeff Fitzgerald. Jeff will assume the role of Director of Business Development.

Jeff brings to EA over a decade of successful sales and support experience with Affymetrix and RainDance Technologies. While at RainDance, Jeff cultivated new business opportunities in research and clinical markets through the use of its sequence enrichment solutions in conjunction with various next generation sequencing platforms. During his sales role at Affymetrix, he supported key genome and academic research centers in the use of expression, resequencing, and genotyping microarrays. Prior to his commercial experience, Jeff sought to identify molecular markers responsible for tumor progression while performing research in the Department of Pathology at Brigham and Women’s Hospital and Harvard Medical School. Jeff received his Bachelor of Science degree in Microbiology and Molecular Genetics from the University of Vermont.

“We are very pleased to have Jeff join us here at EA,” says Steve McPhail, CEO and President of Expression Analysis. “His experience and wealth of knowledge will greatly benefit the company as we continue to expand our services and customer base.”

About Expression Analysis

Expression Analysis (www.ExpressionAnalysis.com) provides whole genome to focused set gene expression and genotyping assays along with DNA sequencings services, sequence enrichment technologies and bioinformatics support. Platforms utilized include Affymetrix GeneChip®, Agilent Sure Select Target Enrichment System, Fluidigm’s Biomark and Access Array Systems, Illumina BeadChip®, iScan, HiSeq and Genome Analyzer, Raindance Technologies RDT 1000 and the Pacific Biosciences PacBio RS. Expression Analysis offers solutions for challenging specimens such as whole blood and FFPE tissues, as well as nucleic acid isolation and data analysis services. Our quality system follows CLSI guidelines and our CLIA-registered laboratory supports GLP compliance.



CONTACT:

Expression Analysis
Karen Michailo, 919-287-4277
Mobile: 919-349-3687
[email protected]

KEYWORDS:   United States  North America  North Carolina

INDUSTRY KEYWORDS:   Technology  Data Management  Health  Biotechnology  Genetics

MEDIA:

Logo
 Logo

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.